Durga Prasad Mishra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Durga Prasad Mishra has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Namrata Rastogi
Department of Haematology, Division of Cancer & Genetics, School of Medicine, Cardiff University, Wales, United Kingdom
5 shared publications Abhishek Nirwan
Cell Death Research Laboratory, Endocrinology Division, CSIR-Central Drug Research Institute, B.S. 10/1, Sector-10, Jankipuram Extension Lucknow, Uttar Pradesh 226031, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India
3 shared publicationsAbinash Swain
Cell Death Research Laboratory, Endocrinology Division, CSIR-Central Drug Research Institute, B.S. 10/1, Sector-10, Jankipuram Extension Lucknow, Uttar Pradesh 226031, India
3 shared publicationsRachana Trivedi
Endocrinology Division, Central Drug Research Institute, Uttar Pradesh, 226021, India
3 shared publicationsRakesh Maurya
Medicinal and Process Chemistry Division, Central Drug Research Institute, Uttar Pradesh, 226021, India
3 shared publications- Ravi Thakur
Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, USA
3 shared publications
Latest Publications
- 10 October 2025
- Published by Elsevier in Molecular and Cellular Neuroscience
- Vol. 135, 104050
The LINC00094/miR-19a-3p signalling regulates glycolysis and mediates cold induced traumatic brain injury
- 10 October 2025
- Published by Elsevier in Molecular and Cellular Neuroscience
- Vol. 135, 104050
The LINC00094/miR-19a-3p signalling regulates glycolysis and mediates cold induced traumatic brain injury
- 27 September 2025
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 132, 118421
Diindolylmethane containing peptides inhibit invasion and epithelial-mesenchymal transition associated gene expression in hormone-dependent breast cancer
- 27 September 2025
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 132, 118421
Diindolylmethane containing peptides inhibit invasion and epithelial-mesenchymal transition associated gene expression in hormone-dependent breast cancer
- Open Access
- 18 September 2025
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 192, 118561
Targeting RUNX3/PARP1 signaling ameliorates colorectal cancer cachexia
- 18 September 2025
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 192, 118561
Open AccessTargeting RUNX3/PARP1 signaling ameliorates colorectal cancer cachexia
- Open Access
- 3 September 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (36) , 41342-41358
Targeting Triple Negative Breast Cancer with a Dinuclear Copper(II) Thiocarbohydrazone Complex: Efficacy Evaluation and Cellular Response
The importance of copper complexes in bioinorganic chemistry and medicinal chemistry has been thoroughly documented in the literature. In recent years, extensive studies have focused on copper complexes of Schiff bases that can bind to DNA and proteins, exhibiting significant cytotoxic activity against various cancer cell lines, paving the way for the development of novel copper-based anticancer therapeutics. In this regard, we have synthesized a new dinuclear Cu(II) complex 1 (K38) with a thiocarbohydrazone Schiff base ligand in order to study its anticancer potential. This complex was characterized by HRMS, IR, UV–vis, and EPR spectroscopic studies. The methanol frozen glass of the compound at liquid nitrogen temperature (LNT) exhibited an axial EPR spectrum which was found to contain two sets of parallel lines suggesting the presence of two very weakly interacting Cu(II) centers with average g ∥ = 2.258 and g ⊥ = 2.057 values (approximately) suggesting a pseudo-octahedral or distorted square pyramidal structure of each Cu(II) center with axial (Z) elongation and the unpaired electron being in the d x 2– y 2 orbital of each of the Cu(II) ions. Biological studies revealed strong DNA binding affinity of complex 1, exhibiting an intrinsic binding constant K b of 1.14 × 105 M–1. Further, 1 was also capable of DNA cleavage and DNA fragmentation as observed by TUNEL positive cells. Cytotoxicity assays indicated potent effects against tested breast cancer (BC) cell lines like MDA-MB-231 and MCF-7 where the IC50 values were found to be 0.41 ± 0.03 and 0.89 ± 0.08 μM, respectively. On the other hand, compound 1 was found to be remarkably nontoxic in the nonmalignant breast epithelial MCF-10A cells even at very high concentrations of 1 (75 μM) showing its selectivity toward TNBC (MDA-MB-231) cells. Complex 1 generated substantial ROS as evident from the DCFDA assay. Mechanistic studies using western blot showed a caspase cascade triggered by complex 1 through an intrinsic mitochondrial pathway. Complex 1 led to a decrease in mitochondrial mass, increased mROS, and significant mitochondrial membrane depolarization as evident from MitoTracker, MitoSOX, and TMRM assays, confirming mitochondrial dysfunction leading to cell death.
- 3 September 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (36) , 41342-41358
Open AccessTargeting Triple Negative Breast Cancer with a Dinuclear Copper(II) Thiocarbohydrazone Complex: Efficacy Evaluation and Cellular Response
The importance of copper complexes in bioinorganic chemistry and medicinal chemistry has been thoroughly documented in the literature. In recent years, extensive studies have focused on copper complexes of Schiff bases that can bind to DNA and proteins, exhibiting significant cytotoxic activity against various cancer cell lines, paving the way for the development of novel copper-based anticancer therapeutics. In this regard, we have synthesized a new dinuclear Cu(II) complex 1 (K38) with a thiocarbohydrazone Schiff base ligand in order to study its anticancer potential. This complex was characterized by HRMS, IR, UV–vis, and EPR spectroscopic studies. The methanol frozen glass of the compound at liquid nitrogen temperature (LNT) exhibited an axial EPR spectrum which was found to contain two sets of parallel lines suggesting the presence of two very weakly interacting Cu(II) centers with average g ∥ = 2.258 and g ⊥ = 2.057 values (approximately) suggesting a pseudo-octahedral or distorted square pyramidal structure of each Cu(II) center with axial (Z) elongation and the unpaired electron being in the d x 2– y 2 orbital of each of the Cu(II) ions. Biological studies revealed strong DNA binding affinity of complex 1, exhibiting an intrinsic binding constant K b of 1.14 × 105 M–1. Further, 1 was also capable of DNA cleavage and DNA fragmentation as observed by TUNEL positive cells. Cytotoxicity assays indicated potent effects against tested breast cancer (BC) cell lines like MDA-MB-231 and MCF-7 where the IC50 values were found to be 0.41 ± 0.03 and 0.89 ± 0.08 μM, respectively. On the other hand, compound 1 was found to be remarkably nontoxic in the nonmalignant breast epithelial MCF-10A cells even at very high concentrations of 1 (75 μM) showing its selectivity toward TNBC (MDA-MB-231) cells. Complex 1 generated substantial ROS as evident from the DCFDA assay. Mechanistic studies using western blot showed a caspase cascade triggered by complex 1 through an intrinsic mitochondrial pathway. Complex 1 led to a decrease in mitochondrial mass, increased mROS, and significant mitochondrial membrane depolarization as evident from MitoTracker, MitoSOX, and TMRM assays, confirming mitochondrial dysfunction leading to cell death.
- 8 May 2025
- Published by Elsevier in Biochemical Pharmacology
- Vol. 238, 116979
Coagulin-L alleviates hepatic stellate cells activation and angiogenesis through modulation of the PI3K/AKT pathway during liver fibrosis
- 8 May 2025
- Published by Elsevier in Biochemical Pharmacology
- Vol. 238, 116979
Coagulin-L alleviates hepatic stellate cells activation and angiogenesis through modulation of the PI3K/AKT pathway during liver fibrosis
- 1 March 2024
- Published by Oxford University Press (OUP) in Toxicology Research
- Vol. 13 (2) , tfae058
Short term biodistribution and in vivo toxicity assessment of intravenously injected pristine graphene oxide nanoflakes in SD rats
The present study aimed to elucidate the short term biodistribution of nano sized graphene oxide (GO) along with the toxicological assessment under in-vivo condition with an intent to analyse the toxic effects of sudden accidental exposure of GO The synthesised GO was characterized using UV-Visible spectroscopy, XRD, FTIR, Raman spectroscopy, TGA and DLS. The morphological imaging was performed using SEM, TEM and AFM. With a lateral size of less than 300 nm, these nanoparticles exhibit significant organ barrier permeability of up to 20%. Upon acute exposure to 10 mg/kg dose of ICG-tagged GO nanoflakes through intravenous route, various organs such as kidney, spleen and liver were observed, and the nanoparticles predominantly accumulated in the liver upon 24 h of exposure. Upon confirming the accumulation of these particles in liver through IVIS imaging, our next attempt was to analyse various biochemical and serum parameters. An elevation in various serum parameters such as ALT, AST, Creatinine and Bilirubin was observed. Similarly, in the case of biochemical parameters tested in liver homogenates, an increase in NO, Catalase, GSH, SOD, ROS, LPO, GR, GPx, and GST was observed. This study highlights the potential toxicological risk associated with GO exposure which must be taken into account for any risk analysis associated with GO based consumer products and the occupational hazards.
- 1 March 2024
- Published by Oxford University Press (OUP) in Toxicology Research
- Vol. 13 (2) , tfae058
Short term biodistribution and in vivo toxicity assessment of intravenously injected pristine graphene oxide nanoflakes in SD rats
The present study aimed to elucidate the short term biodistribution of nano sized graphene oxide (GO) along with the toxicological assessment under in-vivo condition with an intent to analyse the toxic effects of sudden accidental exposure of GO The synthesised GO was characterized using UV-Visible spectroscopy, XRD, FTIR, Raman spectroscopy, TGA and DLS. The morphological imaging was performed using SEM, TEM and AFM. With a lateral size of less than 300 nm, these nanoparticles exhibit significant organ barrier permeability of up to 20%. Upon acute exposure to 10 mg/kg dose of ICG-tagged GO nanoflakes through intravenous route, various organs such as kidney, spleen and liver were observed, and the nanoparticles predominantly accumulated in the liver upon 24 h of exposure. Upon confirming the accumulation of these particles in liver through IVIS imaging, our next attempt was to analyse various biochemical and serum parameters. An elevation in various serum parameters such as ALT, AST, Creatinine and Bilirubin was observed. Similarly, in the case of biochemical parameters tested in liver homogenates, an increase in NO, Catalase, GSH, SOD, ROS, LPO, GR, GPx, and GST was observed. This study highlights the potential toxicological risk associated with GO exposure which must be taken into account for any risk analysis associated with GO based consumer products and the occupational hazards.
- Open Access
- 15 March 2022
- Published by Springer Nature in BMC Complementary Medicine and Therapies
- Vol. 22 (1) , 1-19
Anticancer potential of Phoenix dactylifera L. seed extract in human cancer cells and pro-apoptotic effects mediated through caspase-3 dependent pathway in human breast cancer MDA-MB-231 cells: an in vitro and in silico investigation
Background: Phoenix dactyliferaL. has a diverse set of pharmacological properties due to its distinct phytochemical profile. The purpose of this study was to investigate the anticancer potential ofPhoenix dactyliferaseed extract (PDSE) in human breast cancer MDA-MB-231 and MCF-7 cells, as well as liver cancer HepG2 cells, and to investigate the anticancer efficacy in triple-negative MDA-MB-231 cells, followed by in silico validation of the molecular interaction between active components of PDSE and caspase-3, an apoptosis executioner protein .Methods: In this study, human cancer cell lines were cultured and subsequently treated with 10 to 100 μg/mL of PDSE. MTT test was performed to determine the cell viability, MMP was measured using fluorescent probe JC-1, nuclear condensation was determined by Hoechst 33258 dye, Annexin V-FITC & PI staining and cell cycle analysis were evaluated through flow cytometer, and apoptotic markers were detected using western blotting. The bioactive agents in PDSE were identified using high-performance liquid chromatography (HPLC) analysis. The binding affinity was validated using molecular docking tools AutoDock Vina and iGEMDOCK v2.1.Results: Cell viability data indicated that PDSE inhibited cell proliferation in both breast cancer cells and liver cancer cells. MDA-MB-231 cells showed maximum growth inhibition with an IC50value of 85.86 μg/mL for PDSE. However, PDSE did not show any significant toxicity against the normal Vero cell line. PDSE induced MMP loss and formation of apoptotic bodies, enhanced late apoptosis at high doses and arrested cells in the S phase of cell cycle. PDSE activated the enzymatic activity of cleaved caspase-3 and caused the cleavage of poly-ADB ribose polymerase (PARP) protein. PDSE upregulated pro-apoptotic Bax protein markedly but no significant effect on tumor suppressor protein p53, while it downregulated the anti-apoptotic Bcl-2 protein expression. HPLC analysis showed the presence of rutin and quercetin bioactive flavonols in ethanolic extract of PDS. Interestingly, both active components revealed a strong binding interaction with amino acid residues of caspase-3 (PDB ID: 2XYP; Hetero 4-mer - A2B2) protein.Conclusion: PDS could serve as a potential medicinal source for apoptotic cell death in human breast cancer cells and, thus, could be used as a promising and crucial candidate in anticancer drug development. This study warrants further in vivo research, followed by clinical investigation.
- 15 March 2022
- Published by Springer Nature in BMC Complementary Medicine and Therapies
- Vol. 22 (1) , 1-19
Open AccessAnticancer potential of Phoenix dactylifera L. seed extract in human cancer cells and pro-apoptotic effects mediated through caspase-3 dependent pathway in human breast cancer MDA-MB-231 cells: an in vitro and in silico investigation
Background: Phoenix dactyliferaL. has a diverse set of pharmacological properties due to its distinct phytochemical profile. The purpose of this study was to investigate the anticancer potential ofPhoenix dactyliferaseed extract (PDSE) in human breast cancer MDA-MB-231 and MCF-7 cells, as well as liver cancer HepG2 cells, and to investigate the anticancer efficacy in triple-negative MDA-MB-231 cells, followed by in silico validation of the molecular interaction between active components of PDSE and caspase-3, an apoptosis executioner protein .Methods: In this study, human cancer cell lines were cultured and subsequently treated with 10 to 100 μg/mL of PDSE. MTT test was performed to determine the cell viability, MMP was measured using fluorescent probe JC-1, nuclear condensation was determined by Hoechst 33258 dye, Annexin V-FITC & PI staining and cell cycle analysis were evaluated through flow cytometer, and apoptotic markers were detected using western blotting. The bioactive agents in PDSE were identified using high-performance liquid chromatography (HPLC) analysis. The binding affinity was validated using molecular docking tools AutoDock Vina and iGEMDOCK v2.1.Results: Cell viability data indicated that PDSE inhibited cell proliferation in both breast cancer cells and liver cancer cells. MDA-MB-231 cells showed maximum growth inhibition with an IC50value of 85.86 μg/mL for PDSE. However, PDSE did not show any significant toxicity against the normal Vero cell line. PDSE induced MMP loss and formation of apoptotic bodies, enhanced late apoptosis at high doses and arrested cells in the S phase of cell cycle. PDSE activated the enzymatic activity of cleaved caspase-3 and caused the cleavage of poly-ADB ribose polymerase (PARP) protein. PDSE upregulated pro-apoptotic Bax protein markedly but no significant effect on tumor suppressor protein p53, while it downregulated the anti-apoptotic Bcl-2 protein expression. HPLC analysis showed the presence of rutin and quercetin bioactive flavonols in ethanolic extract of PDS. Interestingly, both active components revealed a strong binding interaction with amino acid residues of caspase-3 (PDB ID: 2XYP; Hetero 4-mer - A2B2) protein.Conclusion: PDS could serve as a potential medicinal source for apoptotic cell death in human breast cancer cells and, thus, could be used as a promising and crucial candidate in anticancer drug development. This study warrants further in vivo research, followed by clinical investigation.
- 1 April 2019
- Published by Elsevier in Journal of Hepatology
- Vol. 70 (1) , e194-e195
THU-080-Survivin aggravates fibrogenecity of hepatic stellate cells via mediating TGF-beta/PI3 K/Akt pathway
- 1 April 2019
- Published by Elsevier in Journal of Hepatology
- Vol. 70 (1) , e194-e195
THU-080-Survivin aggravates fibrogenecity of hepatic stellate cells via mediating TGF-beta/PI3 K/Akt pathway